Phase II evaluation of hexamethylmelamine in advanced breast cancer: a Southwest Oncology Group study.

Abstract

Ninety-eight patients with metastatic breast cancer, heavily pretreated with other agents, were entered in a phase II trial of hexamethylmelamine (HEX). Patients were randomized to receive HEX alone or combined with prophylactic pyridoxine. There was a 2% response rate in 89 partially or fully evaluable patients. Seven percent of these patients developed neurologic toxicity which occurred in the HEX-alone group only.

• Authors: C J Fabian, S Rasmussen, R Stephens, A Haut, F Smith, S Balcerzak, B Tranum
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 63 Issue 8 Pg. 1359-61 (Aug 1979) ISSN: 0361-5960 [Print] United States
• PMID: 113095 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Triazines
• Pyridoxine
• Altretamine

Topics

• Aged
• Altretamine (adverse effects, therapeutic use)
• Breast Neoplasms (drug therapy)
• Drug Evaluation
• Female
• Humans
• Middle Aged
• Nausea (chemically induced)
• Nervous System Diseases (chemically induced)
• Pyridoxine (therapeutic use)
• Triazines (therapeutic use)